Quantcast

Reportlinker Adds Kinase Inhibitors: Global Markets

December 2, 2009

NEW YORK, Dec. 2 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:

Kinase Inhibitors: Global Markets

http://www.reportlinker.com/p0166819/Kinase-Inhibitors-Global-Markets.html

Forecasts for the global market, providing data for the years 2005 through 2008, and projections for the market and compound annual growth rates (CAGRs) through 2014

An overview of the market for the kinase inhibitor class of drugs that already are approved and in development, and on the rapidly growing market for kinase inhibitors in key indications, such as cancer and inflammatory disorders

Discussions of the factors such as regulatory issues, the rapidly-changing competitive marketplace, new technologies, and managed-care issues that will affect sales of kinase inhibitors

Detailed company profiles and an evaluation of recent patents.

Chapter- 1: INTRODUCTION

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THIS STUDY 1

INTENDED AUDIENCE 1

SCOPE OF REPORT 2

METHODOLOGY 2

INFORMATION SOURCES 2

AUTHOR’S CREDENTIALS 3

RELATED BCC WORK CREDENTIALS 3

BCC ONLINE SERVICES 3

DISCLAIMER 3

Chapter-2: SUMMARY

SUMMARY 4

SUMMARY TABLE GLOBAL FORECAST OF THE KINASE INHIBITORS (RT, NRT, AND S/T) MARKET BY TYPE, THROUGH 2014 ($ MILLIONS) 5

SUMMARY FIGURE GLOBAL FORECAST OF THE KINASE INHIBITORS MARKET BY TYPE, 2006-2014 ($ MILLIONS) 5

Chapter-3: OVERVIEW

THE CELLULAR ROLE OF KINASES 6

INHIBITORS OF PROTEIN KINASES 7

INHIBITORS OF PROTEIN KINASES (CONTINUED) 8

KINASES AS ATTRACTIVE DRUG TARGETS 9

TABLE 1 ATTRACTIVE FEATURES OF PROTEIN KINASES 10

KINASE INHIBITORS IN CLINICAL USE AND CLINICAL TRIALS 10

TABLE 2 FDA-APPROVED KINASE INHIBITORS 11

TABLE 3 KINASE INHIBITORS IN CLINICAL TRIALS, ORDERED BY PHASE 12

TABLE 3 (CONTINUED) 13

TABLE 3 (CONTINUED) 14

TABLE 3 (CONTINUED) 15

TABLE 3 (CONTINUED) 16

TABLE 3 (CONTINUED) 17

TABLE 4 NUMBER OF KINASE INHIBITORS IN CLINICAL TRIALS, BY PHASE 17

TABLE 5 COMPANIES WITH KINASE INHIBITORS IN CLINICAL TRIALS 17

TABLE 5 (CONTINUED) 18

DATABASES AND LARGE-SCALE INITIATIVES 18

TABLE 6 KINASE DATABASES 19

KINBASE 19

KINASENET 19

KINASE SEQUENCE DATABASE (KSD) 20

KINMUTBASE 21

SCANSITE 21

KINASE PATHWAY DATABASE 22

Chapter-4: TECHNOLOGY OVERVIEW

DEVELOPMENT PROCESS 23

TYPES OF KINASE INHIBITORS 24

TABLE 7 COMPARISON OF TYPES OF INHIBITORS 24

SMALL MOLECULE KINASE INHIBITORS 24

TABLE 8 COMPARISON OF ATP COMPETITIVE AND NONCOMPETITIVE INHIBITORS 25

ATP COMPETITIVE INHIBITORS 25

NON-ATP COMPETITIVE INHIBITORS 25

MONOCLONAL ANTIBODIES 26

ISSUES OF SPECIFICITY 27

ISSUES OF SPECIFICITY (CONTINUED) 28

PROTEIN STRUCTURE AND MODELING 29

RATIONAL DESIGN 30

Chapter-5: PATENT EVALUATION

PATENT SHARE BY KINASE TYPE 31

TABLE 9 KINASE INHIBITOR PATENTS BY TARGET MOLECULE, JULY 2006 TO JULY 2009 (NUMBER) 31

TABLE 10 U.S. AND EU APPROVED KINASE INHIBITORS MAJOR PATENT/EXCLUSIVITY EXPIRATION DATES 32

TABLE 11 KINASE INHIBITOR PATENTS BY ASSIGNEE (NUMBER) 32

TABLE 11 (CONTINUED) 33

Chapter-6: MARKET FOR RECEPTOR TYROSINE KINASE INHIBITORS

TOTAL MARKET SIZE 34

TABLE 12 GLOBAL FORECAST FOR RECEPTOR TYROSINE KINASE INHIBITORS MARKET BY PRODUCT, THROUGH 2014 ($ MILLIONS) 34

FIGURE 1 GLOBAL FORECAST FOR RECEPTOR TYROSINE KINASE INHIBITORS MARKET BY PRODUCT, 2006-2014 ($ MILLIONS) 35

RECEPTOR TYROSINE KINASE BIOLOGY 35

EGFR/HER FAMILY PROTEIN KINASES (EGFR, HER2, HER3, AND HER4) 36

OVERVIEW 36

TABLE 13 EGFR FAMILY INHIBITORS BY STAGE OF CLINICAL DEVELOPMENT (WITH TARGET(S) IN BRACKETS) 37

EGFR INHIBITORS IN CLINICAL USE 38

Erbitux (Cetuximab) 38

Erbitux (Cetuximab) (Continued) 39

Tarceva (Erlotinib) 40

Tarceva (Erlotinib) (Continued) 41

Iressa (Gefitinib) 42

FDA APPROVAL IN THE UNITED STATES 43

FAST TRACK APPROVAL IN JAPAN 44

POST-MARKET STUDIES OF IRESSA 45

Vectibix (Panitumumab) 46

Nimotuzumab 47

GLOBAL MARKET FOR EGFR INHIBITORS 47

TABLE 14 GLOBAL MARKET FOR EGFR INHIBITORS BY REGION, THROUGH 2014 ($ MILLIONS) 47

EGFR INHIBITORS IN DEVELOPMENT 48

Tovok (BIBW 2992) 49

Neratinib (HKI-272) 49

Zactima (Vandetanib, ZD6474) 50

Zalutumumab (HuMax-EGFr) 51

IMC-11F8 51

BMS-690514 52

HER2 INHIBITORS 52

IN CLINICAL USE 52

Herceptin (Trastuzumab) 52

Tykerb/Tyverb (Lapatinib) 53

HER2 INHIBITORS IN CLINICAL DEVELOPMENT 54

ARRY-380 54

INSM-18 55

GLOBAL MARKET FOR HER2 INHIBITORS 55

TABLE 15 GLOBAL MARKET FOR HER2 INHIBITORS BY REGION, THROUGH 2014 ($ MILLIONS) 55

Global Market for HER2 Inhibitors (Continued) 56

VEGF RECEPTOR FAMILY INHIBITORS 57

OVERVIEW 57

TABLE 16 VEGFR FAMILY INHIBITORS BY STAGE OF CLINICAL DEVELOPMENT (WITH TARGET(S) IN BRACKETS) 58

VEGF RECEPTOR INHIBITORS IN CLINICAL USE 58

Nexavar (Sorafenib) 58

Sutent (Sunitinib) 59

Palladia (Toceranib) 60

VEGFR INHIBITORS IN DEVELOPMENT 60

Axitinib (AG-013736) 60

Motesanib (AMG 706) 61

Recentin (Cediranib, AZD2171) 62

Vargatef (BIBF 1120) 63

Pazopanib (GW786034) 64

Ramucirumab (IMC-1121B) 64

Vatalanib (PTK787, ZK222584) 65

Brivanib (BMS-582664) 66

XL184 (BMS-907351) 66

XL880 (GSK1363089) 67

ABT-869 68

GLOBAL MARKET FOR VEGFR INHIBITORS 68

TABLE 17 GLOBAL MARKET FOR VEGFR INHIBITORS BY REGION, THROUGH 2014 ($ MILLIONS) 68

PDGF RECEPTOR FAMILY INHIBITORS 69

OVERVIEW 69

TABLE 18 PDGFR FAMILY INHIBITORS BY STAGE OF CLINICAL DEVELOPMENT (WITH TARGET(S) IN BRACKETS) 70

PDGFR FAMILY INHIBITORS IN DEVELOPMENT 71

Masitinib (AB1010) 71

Tandutinib (MLN518, CT53518) 71

IMC-3G3 72

INS RECEPTOR FAMILY INHIBITORS 72

OVERVIEW 72

INS RECEPTOR FAMILY INHIBITORS IN DEVELOPMENT 73

Figitumumab (CP-751871, CP-751, 871) 73

AMG-479 73

Chapter-7: MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITORS

TOTAL MARKET SIZE AND BACKGROUND 74

TABLE 19 GLOBAL FORECAST FOR NONRECEPTOR TKI MARKET BY PRODUCT, THROUGH 2014 ($ MILLIONS) 74

FIGURE 2 GLOBAL FORECAST FOR NONRECEPTOR TKI MARKET, 2006-2014 ($ MILLIONS) 75

ABL KINASES 76

OVERVIEW 76

ABL INHIBITORS IN CLINICAL USE 76

Gleevec 76

Tasigna (Nilotinib, AMN107) 77

ABL INHIBITORS IN DEVELOPMENT 78

AT9283 78

AP24534 78

Bafetinib (INNO-406) 78

KW-2449 79

XL228 79

GLOBAL MARKET FOR ABL INHIBITORS 79

TABLE 20 GLOBAL FORECAST FOR ABL INHIBITORS MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 79

Global Market for ABL Inhibitors (Continued) 80

SRC KINASES 81

OVERVIEW 81

SRC KINASE INHIBITORS IN CLINICAL USE 82

Sprycel (Dasatinib, BMS-354825) 82

SRC KINASE INHIBITORS IN DEVELOPMENT 83

Bosutinib (SKI-606) 83

AZD0530 84

KX2-391 84

JAK KINASES 85

OVERVIEW 85

JAK INHIBITORS IN DEVELOPMENT 86

CP-690 86

INCB18424 86

INCB28050 87

Lestaurtinib (CEP-701) 87

ONX 0803 (SB1518) 87

TG101348 88

FAKS 88

OVERVIEW 88

FAK INHIBITORS IN DEVELOPMENT 88

PF-00562271 88

PF-04554878 89

Chapter-8: MARKET FOR SERINE/THREONINE KINASE INHIBITORS

TOTAL MARKET SIZE 90

TABLE 21 GLOBAL FORECAST FOR THE STKI MARKET BY PRODUCT, THROUGH 2014 ($ MILLIONS) 90

FIGURE 3 GLOBAL FORECAST FOR THE STKI MARKET, 2006-2014 ($ MILLIONS) 91

MTOR KINASE INHIBITORS 91

OVERVIEW 91

MTOR INHIBITORS IN CLINICAL USE 92

Rapamune (Sirolimus) 92

Certican, Afinitor (Everolimus, RAD001) 92

Certican, Afinitor (Everolimus, RAD001) (Continued) 93

Torisel (Temsirolimus) 94

GLOBAL MARKET FOR MTOR INHIBITORS 94

TABLE 22 GLOBAL MARKET FOR MTOR INHIBITORS* BY REGION, THROUGH 2014 ($ MILLIONS) 95

IN DEVELOPMENT 96

Ridaforolimus, Deforolimus (MK-8669, AP23573) 96

AZD8055 96

BEZ235 96

BGT226 97

OSI-027 97

PF-04691502 97

XL765 97

RHO FAMILY KINASE INHIBITORS 98

OVERVIEW 98

RHO KINASE FAMILY INHIBITORS IN CLINICAL USE 98

Eril (Fasudil Hydrochloride) 98

RHO KINASE FAMILY INHIBITORS IN DEVELOPMENT 99

Cethrin (BA-210) 99

SAR407899A 99

DE-104 99

Y-39983, RKI-983 99

GLOBAL MARKET FOR RHO-KINASE INHIBITORS 99

TABLE 23 GLOBAL MARKET FOR RHO-KINASE INHIBITORS BY REGION, THROUGH 2014 ($ MILLIONS) 100

CYCLIN DEPENDENT KINASES 101

OVERVIEW 101

CDK INHIBITORS IN CLINICAL DEVELOPMENT 101

Alvocidib (Flavopiridol, HMR1275) 101

Seliciclib (CYC202, Roscovitine) 102

P276 103

AT7519 103

PD-0332991 103

P1446 103

PROTEIN KINASE C 103

OVERVIEW 103

PKC INHIBITORS IN CLINICAL DEVELOPMENT 104

Enzastaurin (LY317615) 104

Midostaurin (PKC412) 105

Sotrastaurin (AEB071) 105

KAI-9803 106

KAI-1678 107

PI3K 107

OVERVIEW 107

PI3 KINASE INHIBITORS IN CLINICAL DEVELOPMENT 108

AZD6482 108

BKM120 108

CAL-101 108

CAL-263 108

GDC-0941 (RG7321) 108

GDC-0980 (RG7422) 109

PX-866 109

SF1126 109

XL147 109

AURORA KINASES 110

OVERVIEW 110

AURORA KINASE INHIBITORS IN CLINICAL DEVELOPMENT 110

AZD1152 110

MLN8237 110

PHA-739358 111

CYC116 111

MK-5108 (VX-689) 111

R763 (AS703569) 111

SNS-314 112

TAK-901 112

MAP/MEK KINASES 112

OVERVIEW 112

MEK/P38 INHIBITORS IN CLINICAL DEVELOPMENT 113

AZD6244 113

ARRY-797 114

BMS-582949 114

Losmapimod (GW856553) 114

JUN N-TERMINAL KINASES (JNK) 114Chapter- 1: INTRODUCTION — Complimentary

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THIS STUDY 1

INTENDED AUDIENCE 1

SCOPE OF REPORT 2

METHODOLOGY 2

INFORMATION SOURCES 2

AUTHOR’S CREDENTIALS 3

RELATED BCC WORK CREDENTIALS 3

BCC ONLINE SERVICES 3

DISCLAIMER 3

Chapter-2: SUMMARY

SUMMARY 4

SUMMARY TABLE GLOBAL FORECAST OF THE KINASE INHIBITORS (RT, NRT, AND S/T) MARKET BY TYPE, THROUGH 2014 ($ MILLIONS) 5

SUMMARY FIGURE GLOBAL FORECAST OF THE KINASE INHIBITORS MARKET BY TYPE, 2006-2014 ($ MILLIONS) 5

Chapter-3: OVERVIEW

THE CELLULAR ROLE OF KINASES 6

INHIBITORS OF PROTEIN KINASES 7

INHIBITORS OF PROTEIN KINASES (CONTINUED) 8

KINASES AS ATTRACTIVE DRUG TARGETS 9

TABLE 1 ATTRACTIVE FEATURES OF PROTEIN KINASES 10

KINASE INHIBITORS IN CLINICAL USE AND CLINICAL TRIALS 10

TABLE 2 FDA-APPROVED KINASE INHIBITORS 11

TABLE 3 KINASE INHIBITORS IN CLINICAL TRIALS, ORDERED BY PHASE 12

TABLE 3 (CONTINUED) 13

TABLE 3 (CONTINUED) 14

TABLE 3 (CONTINUED) 15

TABLE 3 (CONTINUED) 16

TABLE 3 (CONTINUED) 17

TABLE 4 NUMBER OF KINASE INHIBITORS IN CLINICAL TRIALS, BY PHASE 17

TABLE 5 COMPANIES WITH KINASE INHIBITORS IN CLINICAL TRIALS 17

TABLE 5 (CONTINUED) 18

DATABASES AND LARGE-SCALE INITIATIVES 18

TABLE 6 KINASE DATABASES 19

KINBASE 19

KINASENET 19

KINASE SEQUENCE DATABASE (KSD) 20

KINMUTBASE 21

SCANSITE 21

KINASE PATHWAY DATABASE 22

Chapter-4: TECHNOLOGY OVERVIEW

DEVELOPMENT PROCESS 23

TYPES OF KINASE INHIBITORS 24

TABLE 7 COMPARISON OF TYPES OF INHIBITORS 24

SMALL MOLECULE KINASE INHIBITORS 24

TABLE 8 COMPARISON OF ATP COMPETITIVE AND NONCOMPETITIVE INHIBITORS 25

ATP COMPETITIVE INHIBITORS 25

NON-ATP COMPETITIVE INHIBITORS 25

MONOCLONAL ANTIBODIES 26

ISSUES OF SPECIFICITY 27

ISSUES OF SPECIFICITY (CONTINUED) 28

PROTEIN STRUCTURE AND MODELING 29

RATIONAL DESIGN 30

Chapter-5: PATENT EVALUATION

PATENT SHARE BY KINASE TYPE 31

TABLE 9 KINASE INHIBITOR PATENTS BY TARGET MOLECULE, JULY 2006 TO JULY 2009 (NUMBER) 31

TABLE 10 U.S. AND EU APPROVED KINASE INHIBITORS MAJOR PATENT/EXCLUSIVITY EXPIRATION DATES 32

TABLE 11 KINASE INHIBITOR PATENTS BY ASSIGNEE (NUMBER) 32

TABLE 11 (CONTINUED) 33

Chapter-6: MARKET FOR RECEPTOR TYROSINE KINASE INHIBITORS

TOTAL MARKET SIZE 34

TABLE 12 GLOBAL FORECAST FOR RECEPTOR TYROSINE KINASE INHIBITORS MARKET BY PRODUCT, THROUGH 2014 ($ MILLIONS) 34

FIGURE 1 GLOBAL FORECAST FOR RECEPTOR TYROSINE KINASE INHIBITORS MARKET BY PRODUCT, 2006-2014 ($ MILLIONS) 35

RECEPTOR TYROSINE KINASE BIOLOGY 35

EGFR/HER FAMILY PROTEIN KINASES (EGFR, HER2, HER3, AND HER4) 36

OVERVIEW 36

TABLE 13 EGFR FAMILY INHIBITORS BY STAGE OF CLINICAL DEVELOPMENT (WITH TARGET(S) IN BRACKETS) 37

EGFR INHIBITORS IN CLINICAL USE 38

Erbitux (Cetuximab) 38

Erbitux (Cetuximab) (Continued) 39

Tarceva (Erlotinib) 40

Tarceva (Erlotinib) (Continued) 41

Iressa (Gefitinib) 42

FDA APPROVAL IN THE UNITED STATES 43

FAST TRACK APPROVAL IN JAPAN 44

POST-MARKET STUDIES OF IRESSA 45

Vectibix (Panitumumab) 46

Nimotuzumab 47

GLOBAL MARKET FOR EGFR INHIBITORS 47

TABLE 14 GLOBAL MARKET FOR EGFR INHIBITORS BY REGION, THROUGH 2014 ($ MILLIONS) 47

EGFR INHIBITORS IN DEVELOPMENT 48

Tovok (BIBW 2992) 49

Neratinib (HKI-272) 49

Zactima (Vandetanib, ZD6474) 50

Zalutumumab (HuMax-EGFr) 51

IMC-11F8 51

BMS-690514 52

HER2 INHIBITORS 52

IN CLINICAL USE 52

Herceptin (Trastuzumab) 52

Tykerb/Tyverb (Lapatinib) 53

HER2 INHIBITORS IN CLINICAL DEVELOPMENT 54

ARRY-380 54

INSM-18 55

GLOBAL MARKET FOR HER2 INHIBITORS 55

TABLE 15 GLOBAL MARKET FOR HER2 INHIBITORS BY REGION, THROUGH 2014 ($ MILLIONS) 55

Global Market for HER2 Inhibitors (Continued) 56

VEGF RECEPTOR FAMILY INHIBITORS 57

OVERVIEW 57

TABLE 16 VEGFR FAMILY INHIBITORS BY STAGE OF CLINICAL DEVELOPMENT (WITH TARGET(S) IN BRACKETS) 58

VEGF RECEPTOR INHIBITORS IN CLINICAL USE 58

Nexavar (Sorafenib) 58

Sutent (Sunitinib) 59

Palladia (Toceranib) 60

VEGFR INHIBITORS IN DEVELOPMENT 60

Axitinib (AG-013736) 60

Motesanib (AMG 706) 61

Recentin (Cediranib, AZD2171) 62

Vargatef (BIBF 1120) 63

Pazopanib (GW786034) 64

Ramucirumab (IMC-1121B) 64

Vatalanib (PTK787, ZK222584) 65

Brivanib (BMS-582664) 66

XL184 (BMS-907351) 66

XL880 (GSK1363089) 67

ABT-869 68

GLOBAL MARKET FOR VEGFR INHIBITORS 68

TABLE 17 GLOBAL MARKET FOR VEGFR INHIBITORS BY REGION, THROUGH 2014 ($ MILLIONS) 68

PDGF RECEPTOR FAMILY INHIBITORS 69

OVERVIEW 69

TABLE 18 PDGFR FAMILY INHIBITORS BY STAGE OF CLINICAL DEVELOPMENT (WITH TARGET(S) IN BRACKETS) 70

PDGFR FAMILY INHIBITORS IN DEVELOPMENT 71

Masitinib (AB1010) 71

Tandutinib (MLN518, CT53518) 71

IMC-3G3 72

INS RECEPTOR FAMILY INHIBITORS 72

OVERVIEW 72

INS RECEPTOR FAMILY INHIBITORS IN DEVELOPMENT 73

Figitumumab (CP-751871, CP-751, 871) 73

AMG-479 73

Chapter-7: MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITORS

TOTAL MARKET SIZE AND BACKGROUND 74

TABLE 19 GLOBAL FORECAST FOR NONRECEPTOR TKI MARKET BY PRODUCT, THROUGH 2014 ($ MILLIONS) 74

FIGURE 2 GLOBAL FORECAST FOR NONRECEPTOR TKI MARKET, 2006-2014 ($ MILLIONS) 75

ABL KINASES 76

OVERVIEW 76

ABL INHIBITORS IN CLINICAL USE 76

Gleevec 76

Tasigna (Nilotinib, AMN107) 77

ABL INHIBITORS IN DEVELOPMENT 78

AT9283 78

AP24534 78

Bafetinib (INNO-406) 78

KW-2449 79

XL228 79

GLOBAL MARKET FOR ABL INHIBITORS 79

TABLE 20 GLOBAL FORECAST FOR ABL INHIBITORS MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 79

Global Market for ABL Inhibitors (Continued) 80

SRC KINASES 81

OVERVIEW 81

SRC KINASE INHIBITORS IN CLINICAL USE 82

Sprycel (Dasatinib, BMS-354825) 82

SRC KINASE INHIBITORS IN DEVELOPMENT 83

Bosutinib (SKI-606) 83

AZD0530 84

KX2-391 84

JAK KINASES 85

OVERVIEW 85

JAK INHIBITORS IN DEVELOPMENT 86

CP-690 86

INCB18424 86

INCB28050 87

Lestaurtinib (CEP-701) 87

ONX 0803 (SB1518) 87

TG101348 88

FAKS 88

OVERVIEW 88

FAK INHIBITORS IN DEVELOPMENT 88

PF-00562271 88

PF-04554878 89

Chapter-8: MARKET FOR SERINE/THREONINE KINASE INHIBITORS

TOTAL MARKET SIZE 90

TABLE 21 GLOBAL FORECAST FOR THE STKI MARKET BY PRODUCT, THROUGH 2014 ($ MILLIONS) 90

FIGURE 3 GLOBAL FORECAST FOR THE STKI MARKET, 2006-2014 ($ MILLIONS) 91

MTOR KINASE INHIBITORS 91

OVERVIEW 91

MTOR INHIBITORS IN CLINICAL USE 92

Rapamune (Sirolimus) 92

Certican, Afinitor (Everolimus, RAD001) 92

Certican, Afinitor (Everolimus, RAD001) (Continued) 93

Torisel (Temsirolimus) 94

GLOBAL MARKET FOR MTOR INHIBITORS 94

TABLE 22 GLOBAL MARKET FOR MTOR INHIBITORS* BY REGION, THROUGH 2014 ($ MILLIONS) 95

IN DEVELOPMENT 96

Ridaforolimus, Deforolimus (MK-8669, AP23573) 96

AZD8055 96

BEZ235 96

BGT226 97

OSI-027 97

PF-04691502 97

XL765 97

RHO FAMILY KINASE INHIBITORS 98

OVERVIEW 98

RHO KINASE FAMILY INHIBITORS IN CLINICAL USE 98

Eril (Fasudil Hydrochloride) 98

RHO KINASE FAMILY INHIBITORS IN DEVELOPMENT 99

Cethrin (BA-210) 99

SAR407899A 99

DE-104 99

Y-39983, RKI-983 99

GLOBAL MARKET FOR RHO-KINASE INHIBITORS 99

TABLE 23 GLOBAL MARKET FOR RHO-KINASE INHIBITORS BY REGION, THROUGH 2014 ($ MILLIONS) 100

CYCLIN DEPENDENT KINASES 101

OVERVIEW 101

CDK INHIBITORS IN CLINICAL DEVELOPMENT 101

Alvocidib (Flavopiridol, HMR1275) 101

Seliciclib (CYC202, Roscovitine) 102

P276 103

AT7519 103

PD-0332991 103

P1446 103

PROTEIN KINASE C 103

OVERVIEW 103

PKC INHIBITORS IN CLINICAL DEVELOPMENT 104

Enzastaurin (LY317615) 104

Midostaurin (PKC412) 105

Sotrastaurin (AEB071) 105

KAI-9803 106

KAI-1678 107

PI3K 107

OVERVIEW 107

PI3 KINASE INHIBITORS IN CLINICAL DEVELOPMENT 108

AZD6482 108

BKM120 108

CAL-101 108

CAL-263 108

GDC-0941 (RG7321) 108

GDC-0980 (RG7422) 109

PX-866 109

SF1126 109

XL147 109

AURORA KINASES 110

OVERVIEW 110

AURORA KINASE INHIBITORS IN CLINICAL DEVELOPMENT 110

AZD1152 110

MLN8237 110

PHA-739358 111

CYC116 111

MK-5108 (VX-689) 111

R763 (AS703569) 111

SNS-314 112

TAK-901 112

MAP/MEK KINASES 112

OVERVIEW 112

MEK/P38 INHIBITORS IN CLINICAL DEVELOPMENT 113

AZD6244 113

ARRY-797 114

BMS-582949 114

Losmapimod (GW856553) 114

JUN N-TERMINAL KINASES (JNK) 114

OVERVIEW 114

JNK INHIBITORS IN CLINICAL DEVELOPMENT 115

Perifosine (KRX-041) 115

Chapter-9: MARKET FOR KINASE INHIBITORS BY DISEASE APPLICATION

TOTAL MARKET SIZE 116

TABLE 24 GLOBAL FORECAST FOR KINASE INHIBITORS MARKET BY CURRENT APPLICATIONS, THROUGH 2014 117

CURRENT APPLICATIONS 117

CANCER 117

Market Size by Kinase Inhibitors 117

TABLE 25 GLOBAL FORECAST FOR KINASE INHIBITORS MARKET IN CANCER TREATMENT BY PRODUCT, THROUGH 2014 ($ MILLIONS) 117

TABLE 26 KINASE INHIBITORS APPROVED TO TREAT CANCER INDICATIONS 118

Types of Cancer 119

Lung Cancer 119

EGFR Inhibitors for Lung Cancer Treatment 120

VEGFR Inhibitors for Lung Cancer 121

Breast Cancer 121

ERB/HER2 Inhibitors for Breast Cancer Treatment 122

Colorectal Cancer 122

EGFR Inhibitors for Colorectal Cancer 123

Pancreatic Cancer 123

EGFR Inhibitors for Pancreatic Cancer Treatment 124

Other Kinase Inhibitors for Pancreatic Cancer 125

Skin Cancers 125

Basal Cell Carcinoma 125

Squamous Cell Carcinoma 126

Melanoma 126

EGFR Inhibitors for Skin Cancer Treatment 127

MAPK/ERK Inhibitors for Skin Cancer Treatment 127

PI3K Inhibitors for Skin Cancer Treatment 127

Ras/Raf Inhibitors in Skin Cancer Treatment 128

Kidney Cancer 128

Kinase Inhibitors in Kidney Cancer 128

Sarcoma 129

Kinase Inhibitors for GIST 129

Liver Cancer 129

Kinase Inhibitors in Liver Cancer 130

Leukemias 130

Chronic Myeloid Leukemia 130

Acute Myeloid Leukemia 131

BCR-ABL Inhibitors for Leukemia Treatment 131

Flt3 Inhibitors for Leukemia Treatment 132

IMMUNE AND INFLAMMATORY DISEASES 133

MARKET SIZE BY KINASE INHIBITORS 133

TABLE 27 WORLDWIDE MARKET FOR KINASE INHIBITORS IN IMMUNE AND INFLAMMATORY DISEASE BY PRODUCT, THROUGH 2014 ($ MILLIONS) 133

Immunosuppression for Organ Transplantation 134

mTOR Inhibitors for Immunosuppression 134

Asthma 135

MAPK Inhibitors in Asthma Treatment 135

Arthritis 136

MAPK Inhibitors in Arthritis Treatment 137

CARDIOVASCULAR DISEASE 137

MARKET SIZE BY KINASE INHIBITORS 138

TABLE 28 GLOBAL FORECAST FOR KINASE INHIBITORS MARKET IN CARDIOVASCULAR DISEASE TREATMENT BY PRODUCT, THROUGH 2014 ($ MILLIONS) 138

Rho Kinases for Cardiovascular Disease 138

MAPK Inhibitors for Cardiovascular Treatment 139

MAPK Inhibitors for … (Continued) 140

MEK/MAPK1 Inhibitors for Cardiovascular Disease 141

JNK inhibitors for Cardiovascular disease 141

EMERGING APPLICATIONS 141

DIABETES 141

VEGF Inhibitors for Treatment of Diabetes 142

FLT3 Inhibitors for Treatment of Diabetes 142

PKC Inhibitors in the Treatment of Diabetes 143

MACULAR DEGENERATION 143

VEGF Inhibitors for Macular Degeneration 144

NEUROLOGICAL DISEASE 145

GSK Kinase Inhibitors for Neurological Disease 145

CDK Inhibitors for Neurological Disease 146

Chapter-10: MAJOR COMPANIES AND MARKET SHARE

MARKET SHARES 147

TABLE 29 KINASE INHIBITOR SALES AND MARKET SHARE OF COMPANIES INVOLVED IN KINASE INHIBITORS, 2008 ($ MILLIONS/%) 147

TABLE 30 SALES AND MARKET SHARE OF COMPANIES INVOLVED IN TKI, 2008 ($ MILLIONS/%) 148

COMPANY PROFILES 148

AB SCIENCE 149

AB Science USA 149

AMGEN 149

ARIAD PHARMACEUTICALS 150

ARRAY BIOPHARMA 150

ASTEX THERAPEUTICS 151

ASTRAZENECA 151

Astrazeneca – U.S. Headquarters 151

AVEO PHARMACEUTICALS 152

BAYER AG 153

Bayer – U.S. Location 153

BOEHRINGER INGELHEIM 154

Boehringer Ingelheim Pharmaceuticals, Inc. 154

BRISTOL-MYERS SQUIBB 154

CEPHALON, INC. 155

CYCLACEL PHARMACEUTICALS 156

Cyclacel – U.S. Location 156

ELI LILLY 157

EXELIXIS 158

GENMAB 158

Genmab – U.S. Location 158

GLAXOSMITHKLINE 159

GlaxoSmithKline – U.S. Location 159

INCYTE 160

KAI PHARMACEUTICALS 160

MERCK KGAA (MERCK SERONO) 161

NOVARTIS 162

Novartis Institutes for BioMedical Research, Inc. 162

ONYX PHARMACEUTICALS 163

OSI PHARMACEUTICALS 163

PFIZER 164

ROCHE (F. HOFFMANN-LA ROCHE, LTD.) 165

SANOFI-AVENTIS 165

TAKEDA 166

TARGEGEN 167

VERTEX PHARMACEUTICALS 167

WYETH 168

Chapter-11: INTERNATIONAL ASPECTS AND REGULATORY ISSUES

MARKET BY REGION 169

TABLE 31 GLOBAL FORECAST FOR KINASE INHIBITORS MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 169

FIGURE 4 REGIONAL SHARE OF GLOBAL MARKET FOR KINASE INHIBITORS, BY REGION 2008 AND 2014 (%) 170

UNITED STATES 171

DRUG WITHDRAWALS 171

MEDICARE 171

OTHER HEALTHCARE CHANGES 172

EUROPEAN UNION 172

NEW DRUG APPROVALS AND INNOVATION 172

DRUG REIMBURSEMENT AND REFERENCE PRICING 173

RELOCATION OF R&D 174

REGULATORY CLIMATE 175

JAPAN 175

NEW DRUG APPROVALS 175

REGULATORY CLIMATE 175

RELATIONSHIP OF ACADEMIA AND INDUSTRY 176

VENTURE CAPITAL 177

Chapter-12: FUTURE DIRECTIONS

SPECIFICITY AND COMPLEXITY 178

RESISTANCE 179

KINASE ACTIVATORS 180

DEVELOPMENTS IN ENABLING TECHNOLOGIES 181

PHOSPHORYLATION-STATE ANTIBODIES 181

Phosphorylation-State Antibodies (Continued) 182

HIGH-THROUGHPUT KINASE ASSAYS 183

HIGH-THROUGHPUT KINASE ASSAYS(CONT) 184

To order this report:

Drug and Medication Industry: Kinase Inhibitors: Global Markets

More Market Research Report


Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker


Source: newswire



comments powered by Disqus